Cellexus Appoints Chief Scientific Officer
Cellexus Biosystems (Cambridgeshire, UK, www.cellexusbiosystems.com) has selected Julie Bick, MD, as its chief scientific officer.
Cellexus Biosystems (Cambridgeshire, UK, www.cellexusbiosystems.com) has selected Julie Bick, MD, as its chief scientific officer. Bick has the worldwide responsibility for leading the company’s research and customer support programs and will be based in the US from the company’s wholly owned subsidiary, Cellexus Biosystems, Inc. Bick is a biochemist with considerable expertise in cell culture and has worked in the areas of protein therapeutics, protein engineering, and assay platform development.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
